Impact of genetic polymorphisms of drug transporters ABCB1 and ABCG2 and regulators of xenobiotic transport and metabolism PXR and CAR on clinical efficacy of dasatinib in chronic myeloid leukemia. Here, ABCG2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.